HopeStage
Back to all studies
CompletedNCT01678755

ABT-126 Compared With Placebo for Cognitive Difficulties in Schizophrenia

About this titleRead the official source — NCT01678755

Researchers compared ABT-126 and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

Medication studyAges 20–55United States
The study in practice

Understand this study

What did researchers investigate?

Researchers compared ABT-126 and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 20 years to 55 years. Other eligibility criteria applied.

Listed locations
Chino and 19 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateAugust 2012
Recruitment status
Completed
Enrollment listed in the registry
157
Sponsor
AbbVie (prior sponsor, Abbott)
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 20 Years to 55 Years
Official registry ID
NCT01678755
Official title
Show the full official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Smokers

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Chino · Garden Grove · National City

17 more locations
  • Oceanside
  • Orange
  • San Diego
  • Torrance
  • Bradenton
  • Maitland
  • Atlanta
  • Chicago
  • Hoffman Estates
  • Lake Charles
  • St Louis
  • Marlton
  • Cedarhurst
  • New York
  • Oklahoma City
  • DeSoto
  • Houston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared ABT-126 and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

Who is behind this study?

The study sponsor is AbbVie (prior sponsor, Abbott).

Did this study involve medication?

Yes. The study involved medication, including ABT-126 and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 20 years to 55 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies